Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ACROMEGALY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,099 records · Page 61Linked to original sources

[G-proteins and endocrine tumors. The example of acromegaly].

Mutations of Gs are found in 30 to 40% of the pituitary tumours responsible for acromegaly (somatotrope tumor), 10% of secreting thyroid tumors, and in the rare McCune-Albright syndrome. Gs is a member of the G protein family, which plays a major role in the mechanism of action of many hormones by coupling their membrane receptors to molecules called effectors, which general intracellular second messengers. Gs is responsible for the coupling of many receptors to adenylate cyclase which synthetizes cyclic AMP. The effect of the mutations of Gs is to permanently activate adenylate cyclase by a mechanism similar to the one exerted by cholera toxin. In the somatotrope cells adenylate cyclase is normally under the control of the hypothalamic hormone GH-RH, which stimulates both growth hormone secretion and cell proliferation. The mutations of Gs allow the somatotrope to escape from the control by GH-RH and to secrete and proliferate in an autonomous way, which leads to the development of a tumor responsible for acromegaly. The same mechanism explains the presence of Gs mutations in the other types of endocrine tumors. Therefore, the mutations transform the gene of Gs into an oncogene, gsp, which represents the first molecular explanation of an old concept familiar to endocrinologists: the autonomy of the secretion and proliferation of endocrine tumors.

Acromegaly↗

Factors determining the long-term outcome of surgery for acromegaly.

Seventy-nine patients with acromegaly were investigated before and after transsphenoidal adenomectomy, to determine the immediate and late outcome, the pre-operative features associated with a good result, and the accuracy of post-operative testing in predicting outcome. Pre-operative evaluation included basal growth hormone (GH), GH response to oral glucose tolerance test (OGTT), GH response to thyrotrophin-releasing hormone (TRH), tests of pituitary reserve, and pituitary scanning to assess tumour size. A few weeks after surgery, these tests were repeated. The patients were recalled for late assessment 1-13 years (median 86 months) after the operation. At the immediate postoperative testing, minimum GH after oral glucose was < or = 2 mU/l in 48.7%, < 5 mU/l in 76.3% and < 10 mU/l in 84.2%. Only 12 patients had GH > 10 mU/l. Basal GH was < or = 2 mU/l in 21%, < 5 in 59.2%, < 10 in 73.6% and < 20 in 90.8%. A minimum GH of < or = 2 mU/l during an OGTT was achieved in 67.4% of patients with intrasellar tumours, compared with 27.3% with extrasellar tumours. Basal GH and post-glucose GH correlated with the late outcome. GH response to TRH showed no correlation with outcome. IGF-1, which could not be assessed in detail, correlated with GH but was not a reliable indicator of outcome. Transsphenoidal adenomectomy is thus a very satisfactory treatment for acromegaly. Postoperative levels of basal growth hormone < 5 mU/l and post-glucose GH < or = 2 mU/l can be regarded as a biochemical cure. Postoperative radiotherapy is not required in patients who achieve a good result. The preoperative factors which significantly influenced the final outcome were basal GH, post-glucose minimum GH, tumour size and impaired pituitary reserve.

Acromegaly↗

[Analysis of blood from the inferior sinus petrosus in patients with Cushing syndrome and acromegaly].

Bilateral catheterization of sinus petrosus inferior was performed in ten patients with Cushing's syndrome and five patients with acromegaly. This was done in order to secure the diagnosis (Cushing's syndrome) and localize an adenoma (Cushing's syndrome and acromegaly). Blood from sinus petrosus inferior on both sides and from the peripheral vein was analyzed for concentration of ACTH or growth hormone after injection of ACTH-releasing hormone and growth hormone-releasing hormone respectively. The quotient between the ACTH concentration in blood from sinus petrosus and peripheral blood determines the diagnosis in Cushing's syndrome and the quotient between the concentration of ACTH or growth hormone between right and left sinus petrosus determines localization of the pituitary adenoma. Correct diagnosis and localization of ACTH-producing pituitary adenoma was found in eight of ten patients with Cushing's syndrome. One result was doubtful and one was wrong. In four patients with Cushing's disease (ACTH-producing adenoma) magnetic tomography (MT) was negative, but catheterization showed the presence of adenoma. In acromegalic patients, correct localization of the adenoma was determined in two out of five patients. In the other three patients, anatomical difficulties prevented satisfactory interpretation.

Acromegaly↗

[Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)].

Long-acting bromocriptine (Parlodel LAR) was used for treatment of 25 patients with acromegaly during the period of 3 to 24 months. Even after the first intramuscular injection of 50 milligrams of the drug a decrease in growth hormone (GH) concentration by at least 50% of the initial values was observed in 28% of patients and an improvement in a sense of well-being in 44%. After 6 months of administration of 100 mg of Parlodel LAR at intervals of 28 days a decrease in GH level by at least 50% was observed in a larger percentage of patients (36.8%), and in 10.5% of them there was a fall of GH concentration to below 10 microU/ml. Side effects, like nausea, vomiting and orthostatic hypotony, appeared within several hours after the injection of Parlodel and lasted in most cases up to 24 hours. After consecutive injections of the drug the side effects were of lesser intensity or completely disappeared. The results obtained allow to conclude that Parlodel LAR is an effective drug in some cases of acromegaly. In most patients the therapeutic effect can be seen after the first injection, but in some cases it appears only after several months of treatment.

Acromegaly↗

Conventional pituitary irradiation in acromegaly. Effect on growth hormone and TSH secretion.

Thirty-one patients who had been treated for acromegaly for 1-21 years with conventional pituitary irradiation were re-examined. Immunoreactive growth hormone (GH) was measured in connection with an oral glucose load. Adrenal and gonadal functions were assessed on the basis of plasma cortisol and the urinary excretion of 17-ketogenic steroids, 17-ketosteroids and gonadotrophins. In evaluating the thyroid-pituitary axis the thyrotrophin-releasing hormone stimulation test (TRH) was used. Initially 30 patients had experienced definite benefit from the treatment but at the time of re-examination 10 still had clinically active disease and required another type of treatment. Normal GH levels (less than 5 ng/ml/1) were seen in only 12 patients. Skin thickness was normal in 15 out of 30. Thus the remission rate can be evaluated as being 67% as regards clinical activity, 50% with regard to skin thickness and 39% in terms of GH levels. Hypogonadism occurred in 12 patients (39%) and adrenal and thyroid failure in 5 patients each (16%). The response to TRH was within the normal range in 2 of the hypothyroid patients. In 22 euthyroid patients the mean increment in serum TSH in response to 200 mug of synthetic TRH was only 5.8 mU/1 which was significantly below the normal mean 12.5 mU/1. Furthermore, in 7 of these patients (32%) the response was absent or subnormal (less than 3.0 mU/1). This indicated that the pituitary is capable of secreting enough TSH for maintenance of an euthyroid state but that its capacity is limited. Conventional pituitary irradiation is not a very effective treatment in acromegaly but may still be recommended in selected cases.

Acromegaly↗

High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age.

BACKGROUND: An association between acromegaly and colonic polyps has been reported, although risk factors are still uncertain. METHODS: Full colonoscopy was performed with a fiberoptic colonoscopy on 31 acromegalic patients, 11 men and 20 women aged 27 to 85 years (mean, 52.2 years), and on 236 subjects, 127 men and 109 women aged 23 to 84 years (mean, 50.1 years), referred for hemorrhoids, who were considered controls. The colonoscopic findings were evaluated in relation to demographic, clinical, and hormonal data pertaining to the two groups. RESULTS: The prevalence of either adenomatous or hyperplastic polyps was higher in acromegalic patients than in controls (38% vs 14% and 26% vs 10%, respectively; P < .001, respectively). Acromegalics with and without colonic adenomas did not differ significantly in growth hormone and insulinlike growth factor I levels or duration of acromegalic disease and its status (activity or remission); however, patients with adenoma were younger (median age, 50.5 vs 59 years; range, 27 to 85 years vs 39 to 66 years; P < .05). An opposite age pattern was observed in the control group. Indeed, the prevalence of adenoma in acromegalic patients was much higher than that in controls among those less than 50 years of age (46% vs 7%, P < .001); the difference was less remarkable at older ages. Adenomatous polyps were more frequently found in male subjects, in both patients and controls (45% vs 33% [not significant] and 19% vs 9% [P < .05], respectively). CONCLUSIONS: Acromegaly may carry an increased risk of colonic adenoma, especially in younger patients, who usually display more aggressive disease. A smaller increase in risk was observed in elderly patients, in whom disease is reportedly milder. We suggest that acromegalic patients should undergo screening colonoscopy.

Acromegaly↗

[The place of insulin-like growth factor I in the diagnosis of acromegaly].

Insulin-like growth factor-I (IGF-I) and basal growth hormone (GH) (average of GH values measured at -20 an 0 minutes) levels were measured in 32 (29 treated, 3 untreated) patients with acromegaly. In 15 patients IGF-I and basal GH values were normal. In 12 patients both GH and IGF-I were elevated. In 5 cases normal basal GH and elevated IGF-I levels were found. We assume that elevated serum level of IGF-I is a reliable sign of acromegalic activity. Compared to this, the basal GH level proved to be a much less reliable indicator to predict or exclude active acromegaly (sensitivity: 0.7, specificity: 1, positive predictive value: 1, negative predictive value: 0.75).

Acromegaly↗

[The morphology of the facial skull in patients with active acromegaly based on lateral-view teleroentgenograms].

Measurements of skull base, maxilla and mandible were carried out from lateral teleroentgenograms of the skull made in 27 patients with active acromegaly. Total anterior facial height and mandibular branch height were found the most increased both in men and women. Bone changes of the skull base and facial skeleton in patients with active acromegaly did not depend on the disease duration.

Acromegaly↗

[Neurosurgical treatment of acromegaly].

The results of transsphenoidal surgery in 45 consecutive patients with pituitary adenoma and acromegaly are reviewed. The cure rate defined in clinical terms is specifically related to the size of the adenoma. 20 out of 21 patients with intrasellar adenomas were cured by surgery. Of 24 patients with extrasellar adenomas eight were cured and ten had improved, while six had no clinical effect of the operation. Overall 62.2% were cured, 24.4% had improved and 13.3% were unchanged. The complications were 3 patients with pituitary insufficiency, rhinoliquorrhoea successfully treated with surgery in one patient, and an internal carotid artery lesion treated with trapping without sequelae in one patient. No recurrences were observed over two years. It is concluded that treatment of acromegaly is teamwork for internists and surgeons, and that transsphenoidal pituitary surgery is at present the primary treatment of choice.

Acromegaly↗

[Bone density of the lumbar spine and femur in acromegaly].

Acromegaly is regarded as a cause for secondary osteoporosis, whereas recent papers suggest that growth hormone increases bone mineral density (BMD). In 16 patients with active acromegaly we found an increased BMD compared to normal controls in the lumbar spine and the proximal femur by means of dual energy X-ray absorptiometry. This increase in BMD was statistically significant in the femoral neck and in Ward's triangle (P = 0.05). Moreover, no signs of osteoporosis were found radiologically.

Absorptiometry, Photon↗

Heart disease in acromegaly.

Evidence has accumulated regarding acromegalic heart muscle disease which existence now appears to be unequivocal. We took an advantage of a large group of acromegalic patients being followed-up at our institution for a long time and have studied pattern, nature and reversibility of acromegalic heart disease. Its major manifestation is cardiac hypertrophy expressed especially as left ventricular hypertrophy. The cardiac hypertrophy is slowly reversible after normalization of plasma growth hormone levels due to successful treatment. This we have first suggested on the basis of a retrospective analysis of clinical and echocardiographic data in 78 patients with acromegaly and subsequently confirmed by a 10-year prospective follow-up of the original patient cohort. We have also showed that effective treatment of acromegaly with a new slow release somatostatine analogue lanreotide leads to regression of cardiac hypertrophy.

Acromegaly↗

Comparison of different body composition models in acromegaly.

The aberrant body composition of 10 patients with active acromegaly was used to evaluate the validity and limitations of several models and methods to assess body composition. Body composition was determined using either a two-compartment model, dividing the body in a body fat (BF) compartment and a fat-free mass (FFM) compartment, or a four-compartment model in which the FFM compartment comprises the three following components: body cell mass, extracellular water and the fat-free extracellular solids. The measurement techniques consisted of anthropometry, bioelectrical impedance analysis (BIA)-applying various established regression equations-tritiated water dilution, whole body 40K-counting, and whole body computed tomography (CT). This latter method was used as the reference technique. Assessment of total body water using BIA - applying the RJL or Kushner equation-correlated significantly with the assessment using tritiated water dilution (P < 0.01). Body fat assessment using the two-compartment model based on either tritiated water dilution or BIA-applying the RJL or Lukaski equation-as well as body fat assessment using the four-compartment model based on tritiated water dilution and whole body 40K-counting were significantly correlated with body fat assessment using CT (P < 0.01) and resulted in good agreement with each other with respect to the absolute values of the body fat determination. BIA using other regression equations overestimated body fat by 7.2-13.7 kg. Whole body 40K-counting was significantly correlated with CT-determined muscle plus skin volume (P < 0.001). CT-calibrated anthropometric predictions significantly overestimated body fat. It is concluded that in patients with active acromegaly, the determination of body composition using either certain two-compartment models based on measurement of total body water or bioelectrical impedance, or a four-compartment model based on total body water and total body potassium measurements show good agreement with CT-determined body composition.

Acromegaly↗

Body composition and skeletal metabolism following pituitary irradiation in acromegaly.

The change in body composition in acromegaly that resulted from pituitary irradiation was examined using the technic of total body neutron activation analysis. Before treatment, increased ratios of total body P:Ca, P:K and Na:K were noted. After pituitary irradiation, the total body levels of P, Na and K were reduced in a proportion that indicated restoration of body composition towards normal. Skeletal mass (total body calcium) decreased into the range observed in osteoporosis in several patients. Trabecular bone mass, as reflected by the Singh Index, was consistently reduced, and two patients had vertebral compression fractures. Local bone mass as determined by photon absorptiometry was reduced when the values were normalized for age, sex and body size. It is postulated that in untreated acromegaly there is differential bone remodelling with an increase in cortical bone accompanied by a reduced trabecular bone mass. When reduction of hGH levels is accomplished with treatment, cortical apposition may decrease. Since the increased cortical bone mass probably aids in preventing vertebral compression fractures, the treated acromegalic patient may incur an increased risk of fractures. This risk may be increased further by the hypogonadism which may arise secondary to pituitary irradiation or surgery. It would be prudent to ensure that the hypogonadal acromegalic patient receives an adequate calcium intake and sex hormone replacement therapy.

Acromegaly↗

Heavy-particle therapy in acromegaly and Cushing disease.

A total of 349 patients with pituitary tumors, including acromegaly, Cushing disease, Nelson syndrome, prolactin-secreting adenoma, and chromophobe adenoma, have been treated with heavy-particle radiation during the past 17 years. The incidence of side effects has been low. Only 30 patients, 8.6%, have died, most of preexisting cardiovascular complications. Heavy particle therapy provides a form of treatment with no mortality and extremely low morbidity, and its use in treating pituitary disorders has resulted in dramatic improvement in the signs and symptoms of patients with acromegaly and Cushing disease.

Acromegaly↗

[Acromegaly with the sleep apnea syndrome].

The authors present the clinical of a male patient aged 45 years whose main complaints were loud snoring and excessive daytime sleepiness. Polysomnographic study revealed a sleep obstructive apnea syndrome with an apnea/hypopnea index of 86.5. After being treated with nasal continuous positive air pressure, (12 cm H2O), the apneas ended and sleep architecture was corrected. Physical examination also indicated the presence of an acromegaly, and therefore, the patient was subjected to endocrinological and cerebral imagiological studies; the diagnosis confirmed it as a predisposing factor to the sleep breathing disorder. A brief literature review about the incidence of sleep apnea syndrome in acromegaly is also made; the authors conclude that there is still the need for a systematic screening of sleep breathing disorders in acromegalic patients in order to optimise the treatment and prognosis of this disorders.

Acromegaly↗

Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance.

A 22-year-old Chinese woman presented with typical features of diabetic ketoacidosis. There was a family history of diabetes but she was not obese. Plasma glucose and bicarbonate levels were 27.0 mmol/l and 5 mmol/l, respectively. Significant insulin resistance was noticed: she needed up to 15 units of insulin per hour. She required up to 120 units daily for her diabetic control even after her acidosis had subsided. She was then noticed to have the clinical features of acromegaly. The diagnosis was confirmed, and a cranial CT scan confirmed the presence of a pituitary macroadenoma. She underwent uneventful trans-sphenoidal resection of the tumour and her insulin requirement gradually lessened. Acromegaly should be considered in the differential diagnosis of unexplained insulin resistance.

Acromegaly↗

Diabetes in acromegaly--a study of 34 cases.

The incidence and severity of diabetes mellitus (DM) in 34 patients with acromegaly were studied. The incidence was higher (55.9%) than any other series reported. Nineteen had DM, of which 10 were symptomatic. Only one had diabetic retinopathy. Glucose tolerance was improved after successful treatment of acromegaly.

Acromegaly↗

Cobalt 60 irradiation of pituitary gland tumors in three cats with acromegaly.

Acromegaly was diagnosed in 3 cats with insulin-resistant diabetes mellitus (DM) on the basis of history and physical examination findings, which ruled out other causes of insulin-resistant DM, and by documenting high plasma concentrations of growth hormone. Computed tomography revealed a mass in the area of the pituitary gland in each cat. Pituitary gland tumors were irradiated with cobalt 60, and none of the cats developed complications to radiotherapy. Each cat received a total dose of 48 Gy of cobalt 60 during 12 treatments. After completion of radiotherapy, insulin requirements were less for all cats, although in 1 cat, this improvement was transient. Diabetes mellitus resolved in 2 of 3 cats. After treatment, decreases in insulin requirements correlated with decreases in plasma growth hormone concentrations in 2 of 3 cats in which DM resolved. On the basis of these findings, irradiation of pituitary gland tumors appears to be a treatment option for cats with acromegaly.

Acromegaly↗